Janssen Scores FDA Approval For New Schizophrenia Drug
Janssen Pharmaceuticals Inc. said Tuesday that the U.S. Food and Drug Administration has approved a new version of a Johnson & Johnson schizophrenia treatment that only requires four doses per year....To view the full article, register now.
Already a subscriber? Click here to view full article